Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies

Journal of Nuclear Medicine

Volumn 47, Issue 3, 2006, Pages 410-418

  Cher, Lawrence M ^a   Murone, Carmel ^a   Lawrentschuk, Nathan ^a,b   Ramdave, Shanker ^a   Papenfuss, Anthony ^c   Hannah, Anthony ^a   O'Keefe, Graeme J ^a   Sachinidis, John I ^a   Berlangieri, Salvatore U ^a   Fabinyi, Gavin ^a   Scott, Andrew M ^a,b  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Glioma; PET; Tumor hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; MOLECULAR MARKER; TUMOR MARKER; VASCULOTROPIN RECEPTOR 1; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GLUCOSE; MISONIDAZOLE; OXYGEN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CELL FRACTIONATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; GLIOMA; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; HYPOXIC CELL; IMMUNOHISTOCHEMISTRY; MALE; METABOLIC RATE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; BRAIN; BRAIN TUMOR; CELL HYPOXIA; CLINICAL TRIAL; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); SCINTISCANNING; STATISTICS; VASCULARIZATION;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CELL HYPOXIA; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; GLUCOSE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MISONIDAZOLE; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; RADIOPHARMACEUTICALS; STATISTICS;

EID: 33645969631     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Scott AM. Current status of positron emission tomography in oncology. Australas Radiol. 2002;46:154-162.
2. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150-185.
3. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641-1674.
4. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52.
5. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer. 1988;62:1074-1078.
6. 18F-fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329
7. 18F-Fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 2001;42:679-684.
8. Tewson TJ, Krohn KA. PET radiopharmaceuticals: state-of-the-art and future prospects. Semin Nucl Med. 1998;28:221-234.
9. 18F-Labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl Med Biol. 2000;27:103-112.
10. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661-681.
11. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol Imaging Biol. 2004;6:291-305.
12. 2O. J Nucl Med. 2004;45:1851-1859.
13. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer. 2000;36:1649-1660.
14. Brown JM. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys. 2001;49:319-326.
15. Tsang RW, Fyles AW, Milosevic M, et al. Interrelationship of proliferation and hypoxia in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;46:95-99.
16. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53:113-117.
17. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48:149-156.
18. 18F-FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and vegf expression. Eur J Nucl Med Mol Imaging. 2003;30:695-704.
19. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain memorial award lecture. Cancer Res. 1999;59:5863-5870.
20. 18f-fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
21. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol. 2003;510:285-292.
22. Bernsen HJ, Rijken PF, Peters H, et al. Hypoxia in a human intracerebral glioma model. J Neurosurg. 2000;93:449-454.
23. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
24. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987;111:292-304.
25. Chapman JD, Schneider RF, Urbain JL, Hanks GE. Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. Semin Radiat Oncol. 2001;11:47-57.
26. 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol. 2000;48:228-235.
27. 18F-fluoromisonidazole. Neurology. 1998;51:1617-1621.
28. 18F-fluoromisonidazole PET after intracerebral hemorrhage. Neurology. 1999;53:2179-2182.
29. Liu RS, Chu LS, Yen SH, et al. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med. 1996;23:1384-1387.
30. Caldwell JH, Revenaugh JR, Martin GV, Johnson PM, Rasey JS, Krohn KA. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med. 1995;36:1633-1638.
31. Yeh SH, Liu RS, Wu LC, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med. 1996;23:1378-1383.
32. Rischin D, Peters L, Hicks R, et al. Phase 1 trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:535-542.
33. 18f-fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
34. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260.
35. 18F-fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391-398.
36. 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol. 2003;67:339-344.
37. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133-2137.
38. 18F- Fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology. 2004;64:1202-1207.
39. Kinahan P, Rogers J. Analytic 3-D image reconstruction using all detected events. IEEE Trans Nucl Sci. 1989;36:964-968.
40. 18F]fluoromisonidazole and positron emission tomography following acute ischemic stroke. Neuroimage. 2002;16:425-433.
41. Korkolopoulou P, Patsouris E, Kavantzas N, et al. Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms. Neuropathol Appl Neurobiol. 2002;28:57-66.
42. Zar J. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice Hall; 1999.
43. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers - recent trends in incidence and mortality. J Natl Cancer Inst. 1999;91:1382-1390.
44. Giles GG, Armstrong BK, Smith LR, eds. Cancer in Australia 1982. Canberra: Australasian Association of Cancer Registries and Australian Institute of Health. National Cancer Statistics Clearing House. Scientific Publication no. 1, 1987.
45. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
46. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther. 2002;1:453-458.
47. 18F-fluoromisonidazole (FMISO). Nucl Med Biol. 2002;29:191-197.
48. Imaya H. Lactate metabolism conducted by rat c6-glioma in the cells culture. J Neurosurg Sci. 1994;38:223-227.
49. Bottaro DP, Liotta LA. Cancer: out of air is not out of action. Nature. 2003;423:593-595.
50. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med. 2003;138:659-668.
51. Zanetta L, Marcus SG, Vasile J, et al. Expression of von willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int J Cancer. 2000;85:281-288.
52. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Papadakis N, Varakis I. Microvessel density in brain tumors. Anticancer Res. 1997;17:4747-4753.
53. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88:2606-2618.
54. Adesina AM, Leech RW, Brumback RA. Histopathology of primary tumors of the central nervous system. In: Prados M, ed. Brain Cancer: American Cancer Society Atlas of Clinical Oncology. Hamilton, Ontario, Canada: BC Decker Inc.; 2002:16-47.
55. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of hif-1alpha in response to hypoxia is instantaneous. FASEB J. 2001;15:1312-1314.
56. Stroka DM, Burkhardt T, Desbaillets I, et al. Hif-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001;15:2445-2453.
57. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D. Prognostic significance of ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol. 1998;24:381-388.
58. Park SH, Suh YL. Expression of cyclin a and topoisomerase iialpha of oligodendrogliomas is correlated with tumour grade, mib-1 labelling index and survival. Histopathology. 2003;42:395-402.
59. McKeever PE, Strawderman MS, Yamini B, Mikhail AA, Blaivas M. Mib-1 proliferation index predicts survival among patients with grade ii astrocytoma. J Neuropathol Exp Neurol. 1998;57:931-936.
60. Heesters MA, Koudstaal J, Go KG, Molenaar WM. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neurooncol. 1999;44:255-266.
61. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
62. Machein MR, Plate KH. Vegf in brain tumors. J Neurooncol. 2000;50:109-120.
63. Parliament MB, Allalunis-Turner MJ, Franko AJ, et al. Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br J Cancer. 2000;82:635-641.
64. Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H. Prognostic value of vascular endothelial growth factor and its receptors flt-1 and flk-1 in astrocytic tumours. Acta Neurochir (Wien). 2001;143:159-166.
65. Kleinberg L, Grossman SA, Carson K, et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol. 2002;20:3149-3155.
66. Hustinx R, Eck SL, Alavi A. Potential applications of PET imaging in developing novel cancer therapies. J Nucl Med. 1999;40:995-1002.